First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Stephen V. Liu, Florian Huemer et al.|New England Journal of Medicine|2018Cited by 3.5k
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung CancerPrimo N. Lara, Giorgio V. Scagliotti, Jean‐Yves Douillard et al.|Journal of Clinical Oncology|2011Cited by 320
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Stephen V. Liu, Rafał Dziadziuszko et al.|Lung Cancer|2024Cited by 66